Sit Investment Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Sit Investment Associates’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.24M	Buy	69,650 +825	+1%	+$39.6K	0.06%	249
2026 Q1	$3.56M	Buy	68,825 +3,625	+6%	+$185K	0.07%	236
2025 Q4	$3.24M	Buy	65,200 +250	+0.4%	+$12.2K	0.06%	247
2025 Q3	$3.1M	Hold	64,950	–	–	0.06%	262
2025 Q2	$2.05M	Buy	64,950 +26,150	+67%	+$838K	0.04%	302
2025 Q1	$1.27M	Hold	38,800	–	–	0.03%	349
2024 Q4	$1.4M	Hold	38,800	–	–	0.03%	349
2024 Q3	$1.21M	Hold	38,800	–	–	0.03%	365
2024 Q2	$1.04M	Hold	38,800	–	–	0.02%	361
2024 Q1	$1.32M	Buy	38,800 +29,350	+311%	+$874K	0.03%	339
2023 Q4	$273K	Buy	+9,450	New	+$251K	0.01%	448
2019 Q3	–	Sell	-19,750	Closed	-$654K	–	542
2019 Q2	$654K	Hold	19,750	–	–	0.02%	378
2019 Q1	$692K	Hold	19,750	–	–	0.02%	371
2018 Q4	$656K	Hold	19,750	–	–	0.02%	368
2018 Q3	$994K	Buy	19,750 +2,550	+15%	+$126K	0.03%	334
2018 Q2	$1.03M	Hold	17,200	–	–	0.03%	354
2018 Q1	$788K	Buy	+17,200	New	+$718K	0.02%	375

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Sit Investment Associates's SUPN Position: Q2 2026 in Review

Sit Investment Associates increased its Supernus Pharmaceuticals (SUPN) stake by 1.2% in Q2 2026, buying an estimated $39.6K and bringing the position to 69,650 shares worth $3.24M. The position accounts for 0.06% of the portfolio, ranked #249.

Sit Investment Associates first reported a position in SUPN in Q1 2018 and has held it in 17 quarters since. The position peaked at $3.56M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Sit Investment Associates held 69,650 shares of Supernus Pharmaceuticals worth $3.24M as of Q2 2026.
Sit Investment Associates bought 825 Supernus Pharmaceuticals shares in Q2 2026, an estimated $39.6K.
Supernus Pharmaceuticals made up 0.06% of Sit Investment Associates's portfolio in Q2 2026, its #249 holding.
Sit Investment Associates first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 17 quarters since.
Sit Investment Associates's Supernus Pharmaceuticals position peaked at $3.56M in Q1 2026.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.